SUTRO BIOPHARMA, INC. (STRO)
About SUTRO BIOPHARMA, INC.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $102.5M
- Net income
- -$191.1M
- Total assets
- $173.8M
- Market cap
- $432.3M
- Operating margin
- -154.5%
- Net margin
- -186.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $102.5M
- Operating expenses
- $260.9M
- Operating income
- -$158.4M
- Income tax
- -$93.0K
- Net income
- -$191.1M
- EPS (basic)
- $-22.49
- EPS (diluted)
- $-22.49
Balance sheet
- Total assets
- $173.8M
- Current assets
- $150.9M
- Total liabilities
- $306.3M
- Current liabilities
- $75.1M
- Shareholders’ equity
- -$132.5M
Cash flow
- Operating cash flow
- -$177.2M
- Investing cash flow
- $45.0M
- Financing cash flow
- $44.0K
- Net cash flow
- -$132.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $432.3M
- EPS (diluted)
- $-22.49
- Shares outstanding
- 18.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 27, 2018
Sutro Biopharma, Inc. (STRO) Stock Price
- Reported a net loss of $191.1M in FY2025.
- Revenue grew 66% from FY2021 to FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SUTRO BIOPHARMA, INC..
Write a review
News about SUTRO BIOPHARMA, INC.
News & sentiment via Polygon.io
Sutro Biopharma, Inc.: frequently asked questions
Is Sutro Biopharma, Inc. an American company?
Sutro Biopharma, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Sutro Biopharma, Inc. headquartered?
Sutro Biopharma, Inc. is headquartered in South San Francisco, California, United States.
Is Sutro Biopharma, Inc. publicly traded?
Yes — Sutro Biopharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol STRO on the NASDAQ.
What does Sutro Biopharma, Inc. do?
Sutro Biopharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Sutro Biopharma, Inc. founded?
Sutro Biopharma, Inc. was founded in 2003.
